MONEY

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Read More

Tags:

Previous Article

The Declaration of Independence and current threats to liberal democracy

Next Article

Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivone...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

ECB will probably cut rates in Oct on risk of too low inflation: Villeroy

ECB will probably cut rates in Oct on risk of too low i...

Tomas Kauer - Mode... Oct 7, 2024

Five Ukraine-launched drones downed in Russia's Tver region near Moscow, governor says

Five Ukraine-launched drones downed in Russia's Tver re...

Tomas Kauer - Mode... Sep 1, 2024

Argentina's August inflation still stubborn as residents struggle to save

Argentina's August inflation still stubborn as resident...

Tomas Kauer - Mode... Sep 12, 2024